Absolute eosinophil count predicts clinical outcomes and toxicity in non-small cell lung cancer patients treated with immunotherapy

Cancer Treatment and Research Communications

卷:32

Francesca Mazzoni¹  Sara Fancelli¹  Lorenzo Antonuzzo²  Carlotta Ottanelli³  Enrico Caliman³  Marta Rita Gatta Michelet³  Elisa Giommoni³  Serena Pillozzi⁴  Federico Scolari⁵  Daniele Lavacchi⁵  Brunella Napolitano⁵  Luca Voltolini⁵  Luca Paglialunga⁵  Camilla Eva Comin⁵ 

[1] Department of Experimental and Clinical Medicine, University of Florence, Italy;

[2] Thoracic Surgery Unit, Careggi University Hospital, Florence, Italy;

[3] Clinical Oncology Unit, Careggi University Hospital, Florence, Italy;

[4] Medical Oncology Unit, Careggi University Hospital, Florence, Italy;

关键词: Non-small cell lung cancer;    Immunotherapy;    Eosinophils;    Absolute eosinophil count;    Biomarker;   

DOI  :  

来源: DOAJ

【 摘 要 】

Objectives: Immune checkpoint inhibitors (ICIs) have led to a paradigm shift in non-small cell lung cancer (NSCLC) treatment. We investigated absolute eosinophil count (AEC) as a predictor of clinical outcomes and toxicity in NSCLC patients receiving ICIs. Materials and Methods: AEC was retrospectively collected at baseline and during treatment from 158 advanced NSCLC patients treated with single agent anti-PD1/anti-PDL1 monoclonal antibody in first or subsequent line of therapy at Medical Oncology Unit, Careggi University Hospital, Florence (Italy), between January 2016 to October 2020. Results: We found a significant association between high baseline AEC (≥130/μL) and better clinical outcomes. The response rates were 64.4% and 35.6% for patients with high and low AEC, respectively (p = 0.009). The high-AEC group showed a significantly longer PFS and OS than the low-AEC group (mPFS = 7.0 months, 95% CI 5.0–10.0 vs 2.5 months, 95% CI 2.0–4.0, p = 0.007 and mOS = 9.0 months, CI 95% 7.0–15.0 vs 5.5 months, 95% CI 4.0–8.0, p = 0.009, respectively). An increased risk of immune-related adverse events (irAEs) was reported in the high-AEC group (p = 0.133). IrAEs resulted an independent prognostic factor for both better outcomes (mPFS = 8.0 months, 95% CI 7.0–12.0 vs 2.0 months, 95% CI 2.0–3.0, p<0.001; mOS = 13.0 months 95% CI 9.0–19.0 vs 4.0 months 95% CI 3.0–6–0, p<0.001) and response to ICIs (response rate = 33.8% vs 14.9%, disease control rate = 72.0% vs 32.1%, p<0.001). Conclusion: High baseline AEC value (≥130/μL) is a predictive biomarker of clinical benefit and irAEs occurrence in NSCLC patients treated with ICIs.

【 授权许可】

Unknown